
A study evaluated dapagliflozin's effects on patients with type 2 diabetes mellitus (T2D). The study involved a randomized, double-blind, placebo-controlled trial with short-term (1 week) and long-term (12 weeks) cross-over periods. The primary focus was the difference in test meal food intake between long-term dapagliflozin and placebo treatment. While dapagliflozin reduced glycated hemoglobin and body weight, it did not significantly affect food intake, eating rate, energy expenditure, appetite, or brain responses to food cues. However, liver fat decreased significantly with 12 weeks of dapagliflozin use.
Like
Save
Share